The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
Basecamp Research
Frontier AI company designing medicines with EDEN, biological foundation models trained on a large proprietary evolutionary dataset.
What they do
Basecamp Research trains its EDEN foundation models on biodiversity data gathered with partners worldwide and applies them to design long DNA sequences for in vivo cell therapy. In September 2026 it raised a $140M Series C led by S32, taking total funding to about $225M.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI-designed therapeutics
- Product type
- Platform software
- Stage
- Series C
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2019
- Total funding
- $225M raised
Notable investors: S32, NVIDIA, Anthology Fund, NATO Innovation Fund, Redalpine.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Decentralized Clinical Trials Promised Faster Recruitment. The Evidence on Actual Performance Is In.
Dr. Dereck Mush, MD, MBA
Reclaiming Early Clinical Development: Inside the FDA's Expedited IND Pilot
Dr. Dereck Mush, MD, MBA